tradingkey.logo
搜索

MapLight Therapeutics Inc

MPLT
添加自选
7.250USD
+0.180+2.55%
收盘 11-13 16:00(美东)
402.95M总市值
亏损市盈率 TTM

关于 MapLight Therapeutics Inc 公司

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

MapLight Therapeutics Inc 简介

公司代码- -
公司名称- -
上市日期- -
CEO- -
员工数量- -
证券类型- -
年结日- -
公司地址- -
城市- -
上市交易所- -
国家- -
邮编- -
电话- -
网址- -
公司代码- -
上市日期- -
CEO- -

MapLight Therapeutics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
7.86K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%

常见问题

MapLight Therapeutics Inc的前五大股东是谁?

MapLight Therapeutics Inc 的前五大股东如下:Dr. Anatol Kreitzer, Ph.D.
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有